期刊文献+

临床常用保护肾功能药物研究进展 被引量:1

Research progress on clinical commonly medicines for renal function protection
下载PDF
导出
摘要 肾脏疾病在临床十分常见,改善肾脏功能是预防和治疗肾脏疾病的主要方式之一。目前临床常用保护肾脏的药物主要有HMG-CoA还原酶抑制剂、血管紧张素转换酶抑制剂、血管紧张素Ⅱ受体拮抗剂、钙通道阻滞剂、前列腺素、卡培立肽和阿司匹林,其机制与降低血脂、改善内皮的功能、减缓肾间质炎症和纤维化过程、抑制尿蛋白的重吸收、降低血压和改善血流动力学等有关。然而应该注意到这些药物使用不当也可能引起肾功能损害,因此必须严格按照其适应症、疗程和剂量合理使用才可以充分发挥其肾功能保护作用。 Kidney disease was common in clinic, while improving renal function was one of the main ways of the prevention and treatment of kidney disease. At present, the clinical commonly medicines for renal function protection included HMG-CoA reductase inhibitor, angiotensin converting enzyme inhibitor, angiotensin Ⅱ receptor antagonist, calcium channel blocker, prostaglandin, earperitide and aspirin. The mechanisms of those medicines were involved in lowering blood lipid, improving endothelial function, slowing down the process of renal interstitial inflammation and fibrosis, inhibiting the urine protein reabsorption, lowering blood pressure and improving hemodynamics. However, we should notice that improper use of these medicines could also cause kidney function damage. Therefore, we should be in strict accordance with the indications, course and the dose of those medicines for realizing their protection of renal function.
出处 《中国医药科学》 2016年第15期40-43,共4页 China Medicine And Pharmacy
关键词 肾功能 HMG-COA还原酶抑制剂 血管紧张素转换酶 机制 Renal function HMG-CoA reductase inhibitor Angiotensin converting enzyme inhibitor Mechanism
  • 相关文献

参考文献26

  • 1Vidt DG, Harris S, McTaggart F, et al.Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate[J].Am J Cardiol, 2006,97 ( 11 ) : 1602-1606.
  • 2Vidt DG, Cressman MD, Harris S, et al.Rosuvastatin- induced arrest in progression of renal disease[J]. Cardiology, 2004,102 ( 1 ) : 52-60.
  • 3Sandhu S, Wiebe N, Fried LF, et al.Statins for improving renal outcomes: A meta-analysis[J].J Am Soc Nephrol, 2006,17 ( 7 ) : 2006-2016.
  • 4Geng Q, Ren J, Song J, et al.Meta-analysis of the effect of stafins on renal function[J].Am J Cardiol,2014,114 ( 4 ) : 562-570.
  • 5Lamb EJ, Levey AS, Stevens PE.The kidney disease improving global outcomes ( kdigo ) guideline update for chronic kidney disease: Evolution not revolution[J].Clin Chem,2013,59 ( 3 ): 462-465.
  • 6Zoja C, Coma D, Rottoli D, et al.ffect of combining ace inhibitor and statin in severe experimental nephropathy[J]. Kidney Int,2002,61 ( 5 ) : 1635-1645.
  • 7徐月明,蒋旭金,叶中景.苯那普利对慢性肾病病人肾功能的保护作用(附73例报告)[J].中国医师杂志,1999,1(6):61-61. 被引量:1
  • 8Xydakis D, Papadogiannakis A, Sfakianaki M, et al. Residual renal function in hemodialysis patients: The role of angiotensin-converting enzyme inhibitor in its preservation[J].ISRN Nephrol,2013,20 ( 13 ): 184-185.
  • 9Brenner BM, Cooper ME, De Zeeuw D, et al.Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J].N Engl J Med, 2001,345 ( 12 ): 861-869.
  • 10Tanaka R, Kon V, Yoshioka T, et al.Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms[J].Kidney Int, 1994,45 ( 2 ) : 537-543.

二级参考文献15

共引文献2

同被引文献34

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部